Roth Capital Maintains Buy on INFU InfuSystem Holdings, Inc. Feb 24 2026
Roth Capital on Feb 24, 2026 maintained a Buy on InfuSystem Holdings, Inc. (INFU) and lifted its price target to $15, the latest INFU analyst rating update. This move came after InfuSystem’s Q4 2025 call and management guidance for 6% to 8% revenue growth in 2026. Roth’s decision signals continued analyst confidence in InfuSystem’s service margins and IT efficiency gains. Investors should note the firm’s market cap of $174,687,815 and that this report is the only rating action recorded on the date provided.
INFU analyst rating: Roth Capital action and price target change
On Feb 24, 2026 Roth Capital maintained a Buy on InfuSystem and raised its price target to $15 from $14. The action was published by TheFly and reflects Roth’s view after the company’s Q4 2025 disclosures. See the note on price target movement TheFly.
Why this INFU analyst rating matters for investors
A maintained Buy with a higher price target shows the analyst expects steady earnings and upside. Roth’s stance follows management guidance for 6% to 8% revenue growth and record EBITDA, which supports a higher valuation multiple. For investors, the rating reinforces a constructive view but does not guarantee a run higher in the short term.
Earnings context and analyst engagement
Roth Capital participated on InfuSystem’s Q4 2025 call, where company leaders outlined growth drivers and IT efficiency gains. The call transcript is available on Seeking Alpha and provides the context behind Roth’s view Seeking Alpha.
Historical analyst coverage and recent rating trends
Analyst coverage for InfuSystem is limited and Roth is a recurring active watcher. This single maintained Buy on Feb 24, 2026 is the only recent rating change recorded, showing steady rather than shifting analyst sentiment.
Link between the INFU analyst rating and stock performance
The report shows a raised price target but the entry lists no immediate price change. Historically, maintained buys with higher targets can support gradual upside, but actual stock moves depend on execution, guidance revisions, and trading liquidity.
Investor takeaway: positioning after the INFU analyst rating
Investors should weigh Roth’s Buy and $15 target against valuation and execution risk. Use the rating as one data point, check the company’s 2026 guidance, and match risk tolerance to position size given the $174,687,815 market cap.
Final Thoughts
Roth Capital’s action on Feb 24, 2026 kept InfuSystem on a Buy stance and nudged the target to $15, a measured vote of confidence tied to the company’s recent guidance and margin progress. The single recorded INFU analyst rating change signals steady analyst support rather than a change in sentiment. Investors should view the rating as reaffirmation, not proof of imminent upside.
Meyka AI rates INFU with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. Combine analyst signals with company results, guidance tracking, and your risk plan before acting.
FAQs
What was the recent INFU analyst rating change?
On Feb 24, 2026 Roth Capital maintained a Buy on InfuSystem (INFU) and raised its price target to $15. This is the single rating action recorded for that date and reflects post-earnings confidence.
How should investors interpret the INFU analyst rating?
A maintained Buy with a higher price target indicates analyst confidence in growth and margin trends. It supports a positive view but does not replace due diligence on guidance, cash flow, and execution risk.
Did the INFU analyst rating move the stock price?
The provided entry shows no immediate price change. Rating moves can influence sentiment, but price response depends on volume, market context, and company fundamentals.
What is Meyka AI’s assessment after the INFU analyst rating?
Meyka AI rates INFU analyst rating with a stock grade of B+, balancing growth guidance, sector peers, and analyst views. This is an informational grade, not investment advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.